Interstitial Lung DiseaseNCT07833254
Risk Factors of Venous Thrombotic Event in Interstitial Lung Disease
An observational study of Interstitial Lung Disease and Venous Thromboembolism, run by Sohag University.
Trial summary
This study aims to determine the incidence of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), among hospitalized patients with interstitial lung disease (ILD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Interstitial Lung Disease, Venous Thromboembolism, Pulmonary Embolism
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 31 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: "The study will include adult patients aged 18 years or older who are admitted to the Department of Chest Diseases, Sohag University Hospital, with a confirmed diagnosis of interstitial lung disease (ILD). Eligible patients will be assessed for risk factors, clinical characteristics, and occurrence of venous thrombotic events during hospitalization.
Who may be able to join
- Age ≥ 18 years. Patients admitted to the respiratory ICU, Chest Department
Who cannot join
- Age < 18 years. Patients already receiving therapeutic anticoagulation before admission. Known inherited thrombophilia. Active malignancy. Pregnancy. Patients refusing participation. Recent major surgery or trauma within previous 4 weeks.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Incidence , Risk Factors and Clinical Outcomes of Venous Thrombotic Events in Hospitalized Patients With Interstitial Lung Disease
This study aims to determine the incidence of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), among hospitalized patients with interstitial lung disease (ILD). It will also identify potential risk factors associated with VTE and evaluate its impact on clinical outcomes. Patients with ILD admitted to the hospital will be assessed for clinical characteristics, disease severity, risk factors for thrombosis, and the occurrence of DVT or PE during hospitalization. The study findings may help improve early recognition of VTE and guide appropriate preventive and diagnostic strategies in hospitalized patients with ILD.
- Conditions
- Interstitial Lung Disease, Venous Thromboembolism, Pulmonary Embolism, Deep Venous Thrombosis
- Medical subject headings
- Lung Diseases, Interstitial, Venous Thromboembolism, Pulmonary Embolism, Venous Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| One group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary outcome: Incidence of venous thromboembolic events (VTE)
Number and proportion of adult patients with ILD who develop objectively confirmed venous thromboembolic events, defined as DVT and/or pulmonary embolism, during hospitalization.
Measured: One Year
Secondary outcomes (4)
Length of hospital stay
Measured: One year
Requirement and level of respiratory support
Measured: One Year
ICU admission and length of ICU stay
Measured: One Year
In-hospital mortality
Measured: One Year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Interstitial Lung DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Basant Mahmoud Ahmed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07833254
- Sponsor's protocol ID
- Soh-Med-26-7-21MS
- Status last verified
- Sep 2026
- First submitted
- 5 Sep 2026
- Last updated
- 22 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Incidence , Risk Factors and Clinical Outcomes of Venous Thrombotic Events in Hospitalized Patients With Interstitial Lung Disease
- ClinicalTrials.gov ID
- NCT07833254
- Acronym / sponsor ID
- Soh-Med-26-7-21MS
- Conditions
- Interstitial Lung Disease, Venous Thromboembolism, Pulmonary Embolism, Deep Venous Thrombosis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 22 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to determine the incidence of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), among hospitalized patients with interstitial lung disease (ILD). It will also identify potential risk factors associated with VTE and evaluate its impact on clinical outcomes. Patients with ILD admitted to the hospital will be assessed for clinical characteristics, disease severity, risk factors for thrombosis, and the occurrence of DVT or PE during hospitalization. The study findings may help improve early recognition of VTE and guide appropriate preventive and diagnostic strategies in hospitalized patients with ILD.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| One group | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- "The study will include adult patients aged 18 years or older who are admitted to the Department of Chest Diseases, Sohag University Hospital, with a confirmed diagnosis of interstitial lung disease (ILD). Eligible patients will be assessed for risk factors, clinical characteristics, and occurrence of venous thrombotic events during hospitalization.
Key inclusion criteria (1 listed)
- Age ≥ 18 years. Patients admitted to the respiratory ICU, Chest Department
Key exclusion criteria (1 listed)
- Age < 18 years. Patients already receiving therapeutic anticoagulation before admission. Known inherited thrombophilia. Active malignancy. Pregnancy. Patients refusing participation. Recent major surgery or trauma within previous 4 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Primary outcome: Incidence of venous thromboembolic events (VTE)
Time frame: One Year
Number and proportion of adult patients with ILD who develop objectively confirmed venous thromboembolic events, defined as DVT and/or pulmonary embolism, during hospitalization.
4 secondary outcomes
Length of hospital stay
Time frame: One year
Requirement and level of respiratory support
Time frame: One Year
ICU admission and length of ICU stay
Time frame: One Year
In-hospital mortality
Time frame: One Year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
Related trials for Interstitial Lung Disease
RecruitingPhase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary Hypertension, Interstitial Lung Disease
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
RecruitingPhase 3
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
RecruitingObservational study
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Chronic Obstructive Pulmonary Disease (COPD), Smoking
RecruitingPhase 2
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
Fibrotic Interstitial Lung Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitial Lung Disease and Venous Thromboembolism, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Basant MA Omer, M.BB.Ch. (01027894838, Basant.Mahmoud@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary outcome: Incidence of venous thromboembolic events (VTE) (time frame: One Year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.